Secondary Logo

Journal Logo

Protocol Alerts

doi: 10.1097/01.COT.0000577144.70095.d3
News
Free
Back to Top | Article Outline

Clinical Trials in the National Cancer Institute's Database

ACUTE LYMPHOBLASTIC LEUKEMIA

Figure

Figure

Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Status: Active

Phase III

Age: 30 to 70 years

Gender: Male or Female

Location: 412 locations

Primary ID E1910

Secondary IDs NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01

Clinicaltrials.gov ID NCT02003222

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia

Status: Active

Phase III

Age: 18 to 39 years

Gender: Male or Female

Location: 201 locations

Primary ID A041501

Secondary IDs NCI-2016-01981

Clinicaltrials.gov ID NCT03150693

Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Status: Active

Phase III

Age: 1 to 30 years

Gender: Male or Female

Location: 192 locations

Primary ID AALL1131

Secondary IDs NCI-2011-03797, CDR0000706370, NCT01406756, COG-AALL1131, S12-01254

Clinicaltrials.gov ID NCT02883049

Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia

Status: Active

Phase III

Age: 1 to 30 years

Gender: Male or Female

Location: 162 locations

Primary ID AALL1331

Secondary IDs NCI-2014-00631, COG-AALL1331, s15-00970

Clinicaltrials.gov ID NCT02101853

Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Status: Active

Phase III

Age: 2 to 21 years

Gender: Male or Female

Location: 137 locations

Primary ID AALL1631

Secondary IDs NCI-2016-01588

Clinicaltrials.gov ID NCT03007147

Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Status: Active

Phase II

Age: 1 to 21 years

Gender: Male or Female

Location: 127 locations

Primary ID AALL1621

Secondary IDs NCI-2016-01494

Clinicaltrials.gov ID NCT02981628

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients with Acute Lymphoblastic Leukemia

Status: Active

Phase II

Age: 65 years and over

Gender: Male or Female

Location: 156 locations

Primary ID S1318

Secondary IDs NCI-2014-01047, SWOG-S1318

Clinicaltrials.gov ID NCT02143414

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Status: Active

Phase II

Age: 1 to 21 years

Gender: Male or Female

Location: 30 locations

Primary ID INCB 18424-269

Secondary IDs NCI-2016-01687, AALL1521

Clinicaltrials.gov ID NCT02723994

Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia

Status: Active

Phase I/II

Age: 1 year and under

Gender: Male or Female

Location: 11 locations

Primary ID TINI

Secondary IDs NCI-2015-01493

Clinicaltrials.gov ID NCT02553460

A Study Evaluating KTE-X19 in Adult Subjects With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Status: Active

Phase I/II

Age: 18 years and over

Gender: Male or Female

Location: 17 locations

Primary ID KTE-C19-103

Secondary IDs NCI-2015-02272, 2015-005009-35

Clinicaltrials.gov ID NCT02614066

Back to Top | Article Outline

BLADDER CANCER

Pembrolizumab in Treating Patients with Locally Advanced Bladder Cancer

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 644 locations

Primary ID A031501

Secondary IDs NCI-2017-01425

Clinicaltrials.gov ID NCT03244384

Gemcitabine Hydrochloride and Cisplatin in Treating Participants with Invasive Bladder Urothelial Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 290 locations

Primary ID A031701

Secondary IDs NCI-2018-01531

Clinicaltrials.gov ID NCT03609216

Atezolizumab in Treating Patients with Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 248 locations

Primary ID S1605

Secondary IDs NCI-2016-01104

Clinicaltrials.gov ID NCT02844816

Different Versions of BCG with or without Vaccine Therapy in Treating Patients with High Grade Bladder Cancer That Is Not Muscle Invasive

Status: Active

Phase III

Age: Not specified

Gender: Male or Female

Location: 110 locations

Primary ID S1602

Secondary IDs NCI-2016-00451

Clinicaltrials.gov ID NCT03091660

Cisplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor M6620 in Treating Patients with Metastatic Urothelial Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 35 locations

Primary ID 9947

Secondary IDs NCI-2015-01642, PHII-135

Clinicaltrials.gov ID NCT02567409

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 24 locations

Primary ID SGN22E-001

Secondary IDs NCI-2017-01866

Clinicaltrials.gov ID NCT03219333

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

Status: Active

Phase I

Age: 18 years and over

Gender: Male or Female

Location: 24 locations

Primary ID CPI-444-001

Secondary IDs NCI-2016-00227

Clinicaltrials.gov ID NCT02655822

Neratinib HER Mutation Basket Study (SUMMIT)

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 22 locations

Primary ID PUMA-NER-5201

Secondary IDs NCI-2014-00495, 2013-002872-42

Clinicaltrials.gov ID NCT01953926

Back to Top | Article Outline

CERVICAL CANCER

Radiation Therapy with or without Chemotherapy in Patients with Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Status: Active

Phase III

Age: 18 years and over

Gender: Female

Location: 378 locations

Primary ID GOG-0263

Secondary IDs NCI-2011-02037, CDR0000670125

Clinicaltrials.gov ID NCT01101451

Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy

Status: Active

Phase III

Age: 18 years and over

Gender: Female

Location: 151 locations

Primary ID RTOG 0724/GOG-0724

Secondary IDs RTOG-0724, NCI-2011-01973, CDR0000654709, GOG-0724

Clinicaltrials.gov ID NCT00980954

Radiation Therapy and Cisplatin with or without Triapine in Treating Patients with Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Female

Location: 254 locations

Primary ID NRG-GY006

Secondary IDs NCI-2015-00835

Clinicaltrials.gov ID NCT02466971

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Status: Active

Phase I/II

Age: 12 years and over

Gender: Male or Female

Location: 15 locations

Primary ID CA224-020

Secondary IDs NCI-2014-00315, 2014-002605-38

Clinicaltrials.gov ID NCT01968109

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Status: Active

Phase I/II

Age: 18 years and over

Gender: Male or Female

Location: 13 locations

Primary ID ASTX660-01

Secondary IDs NCI-2017-01760

Clinicaltrials.gov ID NCT02503423

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158 / KEYNOTE-158)

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 11 locations

Primary ID 3475-158

Secondary IDs NCI-2015-02278, 163196, 2015-002067-41

Clinicaltrials.gov ID NCT02628067

Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer

Status: Active

Phase III

Age: 18 years and over

Gender: Female

Location: 13 locations

Primary ID ADXS001-02

Secondary IDs NCI-2017-00295

Clinicaltrials.gov ID NCT02853604

Intensity Modulated Radiation Therapy in Treating Patients with Cervical Cancers

Status: Active

Phase II/III

Age: 18 years and over

Gender: Female

Location: 2 locations

Primary ID 110808

Secondary IDs NCI-2012-02858

Clinicaltrials.gov ID NCT01554397

Back to Top | Article Outline

ESOPHAGEAL CANCER

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 20 locations

Primary ID CA209-577

Secondary IDs NCI-2016-00858, 2015-005556-10, s16-00474

Clinicaltrials.gov ID NCT02743494

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590 / KEYNOTE-590)

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 12 locations

Primary ID 3475-590

Secondary IDs NCI-2017-02500, 173739, 2017-000958-19

Clinicaltrials.gov ID NCT03189719

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

Status: Active

Phase I

Age: 18 years and over

Gender: Male or Female

Location: 8 locations

Primary ID DEK-DKK1-P102

Secondary IDs NCI-2014-00704, DKN-01, LY2812176

Clinicaltrials.gov ID NCT02013154

Afatinib Dimaleate and Paclitaxel in Treating Patients with Trastuzumab-Refractory Metastatic Esophagus or Stomach Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 10 locations

Primary ID 11-166

Secondary IDs NCI-2012-00414

Clinicaltrials.gov ID NCT01522768

Pembrolizumab, Trastuzumab, Fluorouracil, and Combination Chemotherapy as First Line Therapy in Treating Patients with HER2-Positive Stage IV Esophagogastric Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 8 locations

Primary ID 16-937

Secondary IDs NCI-2016-01716

Clinicaltrials.gov ID NCT02954536

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Status: Active

Phase I/II

Age: 18 years and over

Gender: Male or Female

Location: 8 locations

Primary ID CP-MGAH22-05

Secondary IDs NCI-2016-00290

Clinicaltrials.gov ID NCT02689284

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Status: Active

Phase I

Age: 18 years and over

Gender: Male or Female

Location: 7 locations

Primary ID CLGK974X2101

Secondary IDs NCI-2011-03693, 2011-000495-33

Clinicaltrials.gov ID NCT01351103

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Status: Active

Phase I/II

Age: 18 years and over

Gender: Male or Female

Location: 8 locations

Primary ID INCAGN 1876-201

Secondary IDs NCI-2017-01296

Clinicaltrials.gov ID NCT03126110

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 5 locations

Primary ID CA209-648

Secondary IDs NCI-2017-00937, 2016-001514-20

Clinicaltrials.gov ID NCT03143153

Durvalumab, Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Esophageal or Gastroesophageal Junction Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 5 locations

Primary ID 16-1405

Secondary IDs NCI-2016-01758

Clinicaltrials.gov ID NCT02962063

Back to Top | Article Outline

GLIOBLASTOMA

Veliparib, Radiation Therapy, and Temozolomide in Treating Participants with Newly Diagnosed Malignant Glioma without H3 K27M or BRAFV600E Mutations

Status: Active

Phase II

Age: 3 to 25 years

Gender: Male or Female

Location: 74 locations

Primary ID ACNS1721

Secondary IDs NCI-2018-01361

Clinicaltrials.gov ID NCT03581292

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 159 locations

Primary ID NRG-BN001

Secondary IDs NCI-2014-01072

Clinicaltrials.gov ID NCT02179086

Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Status: Active

Phase I

Age: 1 to 21 years

Gender: Male or Female

Location: 22 locations

Primary ID ADVL1414

Secondary IDs NCI-2014-02410

Clinicaltrials.gov ID NCT02323880

A Study of TAS-120 in Patients With Advanced Solid Tumors

Status: Active

Phase I/II

Age: 18 years and over

Gender: Male or Female

Location: 20 locations

Primary ID TPU-TAS-120-101

Secondary IDs NCI-2014-01148, 2013-004810-16

Clinicaltrials.gov ID NCT02052778

Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 16 locations

Primary ID 10129

Secondary IDs NCI-2017-01182, 2000023083

Clinicaltrials.gov ID NCT03212274

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Status: Active

Phase I/II

Age: Not specified

Gender: Male or Female

Location: 15 locations

Primary ID SCRX001-006

Secondary IDs NCI-2016-01071

Clinicaltrials.gov ID NCT02709889

Pembrolizumab in Treating Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 13 locations

Primary ID 15-227

Secondary IDs NCI-2016-00116

Clinicaltrials.gov ID NCT02658279

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Status: Active

Phase I/II

Age: 18 years and over

Gender: Male or Female

Location: 14 locations

Primary ID GBM-001

Secondary IDs NCI-2018-00750

Clinicaltrials.gov ID NCT03491683

Abemaciclib, DNA-PK / TOR Kinase Inhibitor CC-115, or Neratinib in Treating Patients with Brain Tumors after Biomarker Screening

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 12 locations

Primary ID 16-443

Secondary IDs NCI-2017-00433

Clinicaltrials.gov ID NCT02977780

Back to Top | Article Outline

LEUKEMIA

Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Status: Active

Phase II

Age: 30 to 70 years

Gender: Male or Female

Location: 412 locations

Primary ID E1910

Secondary IDs NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01

Clinicaltrials.gov ID NCT02003222

Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients with Chronic Myeloid Leukemia

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 375 locations

Primary ID S1712

Secondary IDs NCI-2017-02066

Clinicaltrials.gov ID NCT03654768

Ibrutinib and Obinutuzumab with or without Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia

Status: Active

Phase III

Age: 18 to 69 years

Gender: Male or Female

Location: 319 locations

Primary ID EA9161

Secondary IDs NCI-2018-02127

Clinicaltrials.gov ID NCT03701282

Ibrutinib and Obinutuzumab with or without Venetoclax in Treating Older Patients with Untreated Chronic Lymphocytic Leukemia

Status: Active

Age: 70 years and over

Gender: Male or Female

Location: 216 locations

Primary ID A041702

Secondary IDs NCI-2018-02485

Clinicaltrials.gov ID NCT03737981

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia

Status: Active

Phase III

Age: 18 to 39 years

Gender: Male or Female

Location: 201 locations

Primary ID A041501

Secondary IDs NCI-2016-01981

Clinicaltrials.gov ID NCT03150693

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 186 locations

Primary ID EA9171

Secondary IDs NCI-2017-02161

Clinicaltrials.gov ID NCT03516279

Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Status: Active

Phase III

Age: 1 to 30 years

Gender: Male or Female

Location: 192 locations

Primary ID AALL1131

Secondary IDs NCI-2011-03797, CDR0000706370, NCT01406756, COG-AALL1131, S12-01254

Clinicaltrials.gov ID NCT02883049

Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia

Status: Active

Phase III

Age: 1 to 30 years

Gender: Male or Female

Location: 162 locations

Primary ID AALL1331

Secondary IDs NCI-2014-00631, COG-AALL1331, s15-00970

Clinicaltrials.gov ID NCT02101853

Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia

Status: Active

Phase III

Age: 1 to 21 years

Gender: Male or Female

Location: 153 locations

Primary ID AAML1331

Secondary IDs NCI-2014-02266, PAAML1331_A01PAMDREVW0

Clinicaltrials.gov ID NCT02339740

Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Status: Active

Phase III

Age: 2 to 21 years

Gender: Male or Female

Location: 137 locations

Primary ID AALL1631

Secondary IDs NCI-2016-01588

Clinicaltrials.gov ID NCT03007147

Back to Top | Article Outline

LUNG CANCER

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 1340 locations

Primary ID E4512

Secondary IDs NCI-2014-01507, s16-02072

Clinicaltrials.gov ID NCT02201992

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 1185 locations

Primary ID EAY131

Secondary IDs NCI-2015-00054

Clinicaltrials.gov ID NCT02465060

Durvalumab and Tremelimumab in Treating Patients with Recurrent Stage IV Lung Cancer (A Lung-MAP Treatment Trial)

Status: Active

Phase II

Age: Not specified

Gender: Male or Female

Location: 1041 locations

Primary ID S1400F

Secondary IDs NCI-2016-01597, NCT02154490

Clinicaltrials.gov ID NCT03373760

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 1291 locations

Primary ID A081105

Secondary IDs NCI-2014-01508, s16-02079, CALGB A081105

Clinicaltrials.gov ID NCT02193282

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 839 locations

Primary ID S1609

Secondary IDs NCI-2016-01041

Clinicaltrials.gov ID NCT02834013

Nivolumab after Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 832 locations

Primary ID EA5142

Secondary IDs NCI-2015-01916, s16-02074

Clinicaltrials.gov ID NCT02595944

Three Different Radiation Therapy Regimens in Treating Patients with Limited-Stage Small Cell Lung Cancer Receiving Cisplatin or Carboplatin and Etoposide

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 718 locations

Primary ID CALGB-30610

Secondary IDs NCI-2009-00470, RTOG 0538, CDR0000588879, CALGB 30610/RTOG 0538

Clinicaltrials.gov ID NCT00632853

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 273 locations

Primary ID EA5162

Secondary IDs NCI-2017-01017

Clinicaltrials.gov ID NCT03191149

Whole-Brain Radiation Therapy with or without Hippocampal Avoidance in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer

Status: Active

Phase II/III

Age: 18 years and over

Gender: Male or Female

Location: 240 locations

Primary ID NRG-CC003

Secondary IDs NCI-2015-01548

Clinicaltrials.gov ID NCT02635009

Maintenance Chemotherapy with or without Local Consolidative Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer

Status: Active

Phase II/III

Age: 18 years and over

Gender: Male or Female

Location: 181 locations

Primary ID NRG-LU002

Secondary IDs NCI-2016-00849

Clinicaltrials.gov ID NCT03137771

Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 33 locations

Primary ID SCCC-02515; STU 022015-069

Secondary IDs NCI-2015-01676

Clinicaltrials.gov ID NCT02468024

Back to Top | Article Outline

MELANOMA

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 663 locations

Primary ID EA6134

Secondary IDs NCI-2014-01747

Clinicaltrials.gov ID NCT02224781

Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 637 locations

Primary ID S1320

Secondary IDs NCI-2014-01470, S1221, NCT02199730

Clinicaltrials.gov ID NCT02196181

Ipilimumab with or without Nivolumab in Treating Patients with Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 541 locations

Primary ID S1616

Secondary IDs NCI-2017-00105

Clinicaltrials.gov ID NCT03033576

Pembrolizumab in Treating Patients with Stage III-IV High-Risk Melanoma Before and After Surgery

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 393 locations

Primary ID S1801

Secondary IDs NCI-2018-02107

Clinicaltrials.gov ID NCT03698019

Pembrolizumab in Treating Patients with Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 163 locations

Primary ID S1512

Secondary IDs NCI-2016-00666

Clinicaltrials.gov ID NCT02775851

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1 / 2 / 3 (Trk A / B / C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 28 locations

Primary ID RXDX-101-02

Secondary IDs NCI-2015-01848, 2015 003385 84, GO40782

Clinicaltrials.gov ID NCT02568267

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

Status: Active

Phase I

Age: 18 years and over

Gender: Male or Female

Location: 24 locations

Primary ID CPI-444-001

Secondary IDs NCI-2016-00227

Clinicaltrials.gov ID NCT02655822

Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas

Status: Active

Phase I/II

Age: 1 to 30 years

Gender: Male or Female

Location: 24 locations

Primary ID ADVL1412

Secondary IDs NCI-2014-01222

Clinicaltrials.gov ID NCT02304458

A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors

Status: Active

Phase I/II

Age: 18 years and over

Gender: Male or Female

Location: 20 locations

Primary ID 16-214-02

Secondary IDs NCI-2017-00053

Clinicaltrials.gov ID NCT02983045

Back to Top | Article Outline

PANCREATIC CANCER

Combination Chemotherapy with or without Hypofractionated Radiation Therapy before Surgery in Treating Patients with Pancreatic Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 136 locations

Primary ID A021501

Secondary IDs NCI-2016-00456

Clinicaltrials.gov ID NCT02839343

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1 / 2 / 3 (Trk A / B / C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 28 locations

Primary ID RXDX-101-02

Secondary IDs NCI-2015-01848, 2015 003385 84, GO40782

Clinicaltrials.gov ID NCT02568267

A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 14 locations

Primary ID 9881

Secondary IDs NCI-2015-01097, 1604017576

Clinicaltrials.gov ID NCT02498613

Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer

Status: Active

Phase III

Age: 18 years and over

Gender: Male or Female

Location: 14 locations

Primary ID AM0010-301

Secondary IDs NCI-2017-00276

Clinicaltrials.gov ID NCT02923921

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Status: Active

Phase II

Age: 18 years and over

Gender: Male or Female

Location: 13 locations

Primary ID CA025-006

Secondary IDs NCI-2017-02426

Clinicaltrials.gov ID NCT03336216

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!